<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118817</url>
  </required_header>
  <id_info>
    <org_study_id>HM-RAFI-102</org_study_id>
    <nct_id>NCT03118817</nct_id>
  </id_info>
  <brief_title>Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers</brief_title>
  <official_title>A Single-arm, Open-label, Multi-center, Phase I Expansion Study Evaluating the Efficacy and Safety of HM95573 Monotherapy in Patients With BRAF, KRAS or NRAS Mutation-positive Solid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the anti-tumor efficacy and safety of single agent HM95573 administered&#xD;
      in patients with solid tumors harboring mutations in either BRAF, KRAS or NRAS gene.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2017</start_date>
  <completion_date type="Actual">February 4, 2020</completion_date>
  <primary_completion_date type="Actual">February 4, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (Proportion of patients with reduction in tumor burden of a predefined amount)</measure>
    <time_frame>At screening and every 8 weeks from time of first dosing until date of progression, start of other anticancer therapy or death whichever came first, assessed up to study completion (around 36 months).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability by assessing adverse events (AEs) based on CTCAE ver.4.03</measure>
    <time_frame>All AEs occurring up to 28 days after the last administration of study drug until the start of other anti-cancer treatment, whichever comes first, will be record.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate</measure>
    <time_frame>At screening and every 8 weeks from time of first dosing until date of progression, start of other anticancer therapy or death whichever came first, assessed up to study completion (around 36 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>At screening and every 8 weeks from time of first dosing until date of progression, start of other anticancer therapy or death whichever came first, assessed up to study completion (around 36 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At screening and every 8 weeks from time of first dosing until date of progression, start of other anticancer therapy or death whichever came first, assessed up to study completion (around 36 months).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in molecular biomarkers</measure>
    <time_frame>Screening and 15 days after first dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HM95573</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HM95573</intervention_name>
    <description>Dose: 450 mg BID&#xD;
Regimen: twice daily (BID), continuous dosing&#xD;
Duration: until progression disease or unacceptable toxicity develops</description>
    <arm_group_label>HM95573</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed solid tumor&#xD;
&#xD;
          -  Confirmed mutations in either BRAF, KRAS or NRAS gene&#xD;
&#xD;
          -  Eligible for biomarker analysis as follows:&#xD;
&#xD;
               -  Be able to provide an archival tumor tissue at screening.&#xD;
&#xD;
               -  Consent to undergo pre- and post-treatment tumor biopsies, provided sites of&#xD;
                  disease are easily and safely accessible&#xD;
&#xD;
          -  Tumors for which standard therapy either does not exist or has proven ineffective or&#xD;
             intolerable at study entry;&#xD;
&#xD;
          -  At least one lesion (excluding brain) measureable per Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST) version 1.1;&#xD;
&#xD;
          -  Life expectancy of ≥ 12 weeks;&#xD;
&#xD;
          -  ECOG performance status score 0 or 1;&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hematologic malignancy or double primary cancer.&#xD;
&#xD;
          -  Treatment with any of the following:&#xD;
&#xD;
               -  Anticancer therapy including chemotherapy, hormonal treatment, or radiotherapy&#xD;
                  within 14 days of the first dose of study drug.&#xD;
&#xD;
               -  Investigational (not-approved) agent within 28 days or 5 fold of its half-life&#xD;
                  prior to the first dose of study drug.&#xD;
&#xD;
               -  Major surgical procedure within 28 days prior to the first dose of study drug.&#xD;
&#xD;
               -  Systemic corticosteroid (≥ 10mg prednisolone or equivalent dose of other&#xD;
                  anti-inflammatory corticosteroids) or systemic immunosuppressant within 28 days&#xD;
                  prior to the first dose of study drug or current systemic immunosuppressant which&#xD;
                  is required to be used continuously during treatment period of the study. But&#xD;
                  following treatments will be allowed: topical applications, inhaled sprays, eye&#xD;
                  drops, or local injections.&#xD;
&#xD;
               -  Treatment with nitrosourea, mitomycin, ipilimumab or other immunotherapy within&#xD;
                  42 days prior to the first administration of study drug.&#xD;
&#xD;
               -  &gt;5 prior anticancer therapy regimens&#xD;
&#xD;
          -  Spinal cord compression, leptomeningopathy or other symptomatic or uncontrolled&#xD;
             central nervous system or brain metastasis.&#xD;
&#xD;
          -  Cardiovascular abnormalities as follow:&#xD;
&#xD;
               -  mean QTcF &gt; 440 msec&#xD;
&#xD;
               -  Heart failure of NYHA Class III or IV&#xD;
&#xD;
               -  Heart metastasis&#xD;
&#xD;
               -  Uncontrolled serum electrolyte disturbances (hyponatremia, hypokalemia,&#xD;
                  hypocalcemia or hypomagnesemia)&#xD;
&#xD;
               -  History of acute coronary syndrome including unstable angina and myocardial&#xD;
                  infarction, uncontrolled arrhythmias (except for sinus arrhythmia and atrial&#xD;
                  fibrillation which is controlled within 30 days prior to the first dose of study&#xD;
                  drug), symptomatic congestive heart failure, cerebrovascular accident or&#xD;
                  transient ischemic attack within 6 months prior to the first dose of study drug.&#xD;
&#xD;
               -  History of coronary angioplasty, coronary/peripheral artery bypass graft or stent&#xD;
                  insertion within 6 months prior to the first dose of study drug.&#xD;
&#xD;
               -  History of congenital long QT syndrome or clinically significant ≥ Grade 2&#xD;
                  (NCI-CTCAE version 4.03) ventricular or atrial dysrhythmias.&#xD;
&#xD;
          -  Ophthalmologic disorders as follows:&#xD;
&#xD;
               -  History of or evidence of retinal vein occlusion (RVO), central serous&#xD;
                  retinopathy (CSR) or neovascular macular degeneration at screening&#xD;
&#xD;
               -  Glaucoma with intraocular pressure ≥ 21 mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea, Republic of, Chungcheongbuk-do</name>
      <address>
        <city>Cheongju</city>
        <state>Chungcheongbuk-do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea, Republic of, Gyeonggi-do</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea, Republic of, Gyeongsangbuk-do</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea, Republic of, Seoul</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea, Republic of, Seoul</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea, Republic of, Seoul</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea, Republic of, Seoul</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>August 6, 2020</last_update_submitted>
  <last_update_submitted_qc>August 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

